Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as an important new oral glucose-lowering class of drugs for the management of hyperglycaemia in patients with type 2 diabetes mellitus (DM2). This evidence concerns the gene SLC5A2 and diabetes mellitus.